St. Jude Medical's Trifecta
This article was originally published in The Gray Sheet
Executive Summary
Firm enters the pericardial aortic stented tissue heart valve market with the European debut of Trifecta. St. Jude announced receipt of CE mark clearance for the device March 2. The device's design incorporates a titanium stent as a frame to support the valve leaflets, which are made of pericardial tissue. The "next-generation" tri-leaflet valve "has been specifically designed for improved hemodynamics, durability and implantability," the firm states. The new offering builds on St. Jude's existing valve portfolio, which includes mechanical and porcine tissue valves as well as valve annuloplasty rings